undamentalytics Newsletter
Sign in

DBV Technologies S.a. income statement

In fiscal 2025, DBV Technologies S.a. reported revenue of $5.6m, up 35.8% on the year before, operating income of −$147m (a -2609.2% margin) and net income of −$147m, or −$1.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue15116516464
Research and development11510270766089117144
Selling and marketing22104223317
General and administrative4935312430293351
Operating income−171−159−99−97−76−117−147−208
Income before tax−171−160−98−96−73−114−146−206
Income tax1−0−000001
Net income−172−160−989673−114−147−207
Diluted EPS−$4.65−$2.95−$1.78−$1.24−$0.76−$1.17−$1.05−$0.55
Diluted shares (average)37m54m55m77m95m97m140m374m
EBITDA—−154−94−94−73−114−144—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DBVT vs DYAIALGS vs DBVTCAMP vs DBVT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from DBV Technologies S.a.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to DBV Technologies S.a.